Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
41

Recommended

Meanwhile, value-leaning areas of the market, including industrials and energy stocks, are moving out of undervalued territory.

Rachel Schlueter | 01 March 2026

The results that fell short of market expectations.

Tyger Fitzpatrick | 01 March 2026

Undervalued ASX share on the right track.

Johannes Faul, CFA | 01 March 2026

Index	Last price	Change	% Change
All Ordinaries	9,430.60	80.60	0.86%
CAC 40	8,405.41	175.34	-2.04%
DAX 40	24,715.48	568.78	-2.25%
Dow JONES (US)	48,656.80	321.12	-0.66%
FTSE 100	10,756.56	153.99	-1.41%
HKSE	26,059.85	570.69	-2.14%
NASDAQ	22,554.56	113.65	-0.50%
Nikkei 225	58,057.24	793.03	-1.35%
NZX 50 Index	13,656.65	66.32	-0.48%
S&P 500	6,840.97	37.91	-0.55%
S&P/ASX 200	9,200.90	81.20	0.89%
SSE Composite Index	4,182.59	19.71	0.47%